Standard BioTools reports preliminary $85M in revenue from continuing operations for 2025 above estimates
Source: SeekingAlpha
2026-01-08 07:40:16 ET
Standard BioTools ( LAB ) announced preliminary revenue results for the fourth quarter and full year 2025, expects Q4 revenue of about $56 million, with $24 million from continuing operations vs. consensus of $18.50M....
Read the full article on Seeking Alpha
For further details see:
Standard BioTools reports preliminary $85M in revenue from continuing operations for 2025 above estimates
Standard BioTools Inc.
NASDAQ: LAB
LAB Trading
-2.81% G/L:
$0.9719 Last:
1,211,832 Volume:
$1.0199 Open:
LAB Latest News
February 24, 2026 04:10:00 pm
Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
LAB Stock Data
$476,861,113
295,500,064
21.04%
50
N/A
Biotechnology & Life Sciences
Healthcare
US
Boston
